Linkage Biosciences Closes $2.1M in Funding

(firmenpresse) - SAN FRANCISCO, CA -- (Marketwire) -- 09/08/11 -- Linkage Biosciences, Inc., a molecular diagnostics company and leader in molecular HLA typing products, announced that it raised over $2 million in Series B financing. Linkage Biosciences' LinkS?q™ HLA product line uses a proprietary software and chemistry platform in conjunction with real-time PCR instrumentation. This combination of technologies provides significant improvements in the analysis of complex genetic regions including reducing labor requirements by up to 85% compared to current methods.

Fisher Capital Corp LLC and Greenhouse Capital Partners led the round with all major existing investors from previous rounds participating including Big Sky Partners. "This is an exciting time in the maturation of Linkage Biosciences," said James R. Fisher Sr., Managing Member of Fisher Capital Corp LLC. "With this financing, the company is now positioned to scale up operations to capitalize upon its revolutionary LinkS?q technology."

Zachary Antovich, Linkage's CEO, said the funds will be used to expand manufacturing capabilities, complete regulatory requirements in the US and Europe, and increase the speed to market of additional molecular tests. "Our commercialization plans and technology are progressing rapidly," said Mr. Antovich. "The strong support from our current investors is the result of our continued success in achieving milestones and delivering products that meet or exceed the expectations of our customers."

Linkage Biosciences, Inc. is a privately held molecular diagnostics company developing and marketing products that dramatically improve and expedite complex genetic testing. LinkS?q, the company's HLA testing product line, is used in immunogenetics research. The company is headquartered in San Francisco, California. To learn more please visit .

Copyright 2011. Linkage Biosciences, Inc. All rights reserved.
Linkage Biosciences and LinkS?q are trademarks of Linkage Biosciences, Inc.

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: MARKET WIRE
Datum: 08.09.2011 - 13:00 Uhr
Sprache: Deutsch
News-ID 63606
Anzahl Zeichen: 0

contact information:
Town:

SAN FRANCISCO, CA

Kategorie:

Commercial & Investment Banking

Diese Pressemitteilung wurde bisher 211 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Linkage Biosciences Closes $2.1M in Funding"
steht unter der journalistisch-redaktionellen Verantwortung von

Linkage Biosciences (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Linkage Biosciences Partners With Italian Distributor ...

SAN FRANCISCO, CA -- (Marketwired) -- 04/27/15 -- Linkage Biosciences announced at the 29th European Immunogenetics and Histocompatibility Conference in Geneva, Switzerland a new distribution partnership with Voden Medical Instruments S.p.a. With a ...

Linkage Biosciences Opens European Subsidiary ...

SAN FRANCISCO, CA -- (Marketwired) -- 04/16/15 -- Linkage Biosciences announced the launch of a wholly owned European subsidiary located in Geneva, Switzerland. The launch reflects the company's rapid growth and increasing global demand for Lin ...

Linkage Biosciences Announces Expansion ...

SAN FRANCISCO, CA -- (Marketwired) -- 12/22/14 -- Linkage Biosciences, a leading manufacturer of tissue transplantation diagnostic products, announced a new long-term agreement to add manufacturing, research and development, and office space in Sout ...

Alle Meldungen von Linkage Biosciences